CA125 PET/MRI
Research type
Research Study
Full title
Targeted molecular imaging of CA125 in high grade serous ovarian cancer using 89Zr-DFO-B43.13 positron emission tomography (PET) magnetic resonance imaging (MRI)
IRAS ID
253671
Contact name
Evis Sala
Contact email
Sponsor organisation
Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge
Duration of Study in the UK
2 years, 11 months, 28 days
Research summary
Ovarian cancer cells typically carry protein on their cell surface, namely CA125 (cancer-antigen 125). CA125 can be measured in the blood, and a CA125 blood test can therefore be used to help diagnose ovarian cancer, monitor treatment response and disease recurrence. However, CA125 concentrations in the blood do not reflect the extent of cancer within the body nor can they be used to identify the anatomical location of tumour cells. Knowledge of the exact tumour amount and location could improve treatment planning and surgery.
Positron emission tomography (PET) and magnetic resonance imaging (MRI) are medical imaging methods that can be used to picture cancers and provide information about how tumours function. PET and MRI scans are routinely used in hospitals to detect various cancers, and a PET/MR scan combines these two types of scans into a single examination. To show the activity of the cancer, a mildly radioactive drug (a radiotracer) is used for PET/MRI scanning. The radiotracer used in this study, 89Zr-DFO-B43.13, binds more to cancer cells than normal cells, because cancers display its target protein CA125 on their cell surface while normal cells do not.
This study aims to use a type of scan called an 89Zr-DFO-B43.13 PET/MRI scan in ovarian cancer. We wish to test the ability of this type of scan in identifying the anatomical locations of tumour cells and the extent of ovarian cancer, as this can enable doctors to decide the best course for treatment for each patient. We also wish to compare the results we will be getting from the PET/MRI images, with the results from blood tests and the examination of the tumour tissue following your surgery.REC name
East of England - Cambridgeshire and Hertfordshire Research Ethics Committee
REC reference
19/EE/0097
Date of REC Opinion
5 Jun 2019
REC opinion
Further Information Favourable Opinion